University of Montreal-ko ikertzaileekin lankidetzan egindako argitalpenak (25)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 668-682

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Best practices for applying the Nova food classification system

    Nature Food

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  2. Performance evaluation of the smartphone-based AI cough monitoring app - Hyfe Cough Tracker against solicited respiratory sounds

    F1000Research, Vol. 11

2021

  1. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    EJNMMI Radiopharmacy and Chemistry, Vol. 6, Núm. 1

  2. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January–June 2020)

    EJNMMI Radiopharmacy and Chemistry, Vol. 6, Núm. 1

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  2. The Smc5/6 Core Complex Is a Structure-Specific DNA Binding and Compacting Machine

    Molecular Cell, Vol. 80, Núm. 6, pp. 1025-1038.e5

2019

  1. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e448-e458

2018

  1. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial

    The Lancet, Vol. 391, Núm. 10137, pp. 2325-2334

2016

  1. Centrosome-Dependent Bypass of the DNA Damage Checkpoint by the Polo Kinase Cdc5

    Cell Reports, Vol. 14, Núm. 6, pp. 1422-1434

  2. Checkpoint adaptation: Keeping Cdc5 in the T-loop

    Cell Cycle

2014

  1. Consensus guidelines for the detection of immunogenic cell death

    OncoImmunology, Vol. 3, Núm. 9

  2. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206